{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:40Z","timestamp":1790951440303,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vectura, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite decades of investigations, the optimal assessment of the \u201ctherapeutic response\u201d to early after loading dose of acetylsalicylic acid (ASA) remains unclear. Limited information is available on the relation between pharmacodynamic (PD) and pharmacokinetic (PK) measurements assessed immediately after ASA administration. Serial PD and PK analyses were performed immediately after a single 162 or 650\u00a0mg dose of chewed and swallowed ASA in ten healthy adults. ASA response was defined as\u2009&gt;\u200995% inhibition of serum thromboxane (Tx)B<jats:sub>2,<\/jats:sub>\u2009&lt;\u2009550 aspirin reaction units (ARU) by VerifyNow Aspirin (VN) test, and\u2009\u2264\u200920% arachidonic acid (AA)-induced platelet aggregation (PA). Correlation analyses between PK and PD measurements and receiver operating characteristic (ROC) curve analyses were performed. ASA response measured by VN test and AA-induced PA was achieved within 30\u00a0min of ASA administration. A correlation was observed between ARU and AA-induced maximum PA (r\u2009=\u20090.69, p\u2009&lt;\u20090.001), serum TxB<jats:sub>2<\/jats:sub> (r\u2009=\u20090.74 and p\u2009&lt;\u20090.001), and serum TxB<jats:sub>2<\/jats:sub> inhibition (r\u2009=\u20090.79, p\u2009&lt;\u20090.001). In ROC curve analyses,\u2009\u2264\u2009558 ARU and\u2009\u2264\u20097% AA-induced PA were associated with\u2009&gt;\u200995% inhibition of TxB<jats:sub>2<\/jats:sub>. 686\u00a0ng\/ml plasma ASA cut-off point was associated with\u2009&gt;\u200995% inhibition of serum TxB<jats:sub>2<\/jats:sub>,\u2009\u2264\u20097% 1\u00a0mM AA-induced PA, and\u2009\u2264\u2009585 ARU. A modest\u2009~\u200950% inhibition of TxB<jats:sub>2<\/jats:sub> inhibition was associated with marked inhibition of 1\u00a0mM AA-induced platelet aggregation by LTA. Our analyses demonstrated important relationships between pharmacodynamic, and pharmacokinetic parameters measured immediately following oral ASA and cutoff values for ARU and AA-induced PA that is associated with\u2009&gt;\u200995% inhibition of serum TxB<jats:sub>2<\/jats:sub>.<\/jats:p>","DOI":"10.1007\/s11239-023-02914-7","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T18:02:09Z","timestamp":1702058529000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early assessment of the pharmacokinetic and pharmacodynamic effects following acetylsalicylic acid loading: toward a definition for acute therapeutic response"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5461-568X","authenticated-orcid":false,"given":"Paul A.","family":"Gurbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Bliden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parshotam","family":"Kundan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rueshil","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahib","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind D.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"2914_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcin.2008.01.005","volume":"1","author":"DJ Kereiakes","year":"2008","unstructured":"Kereiakes DJ, Gurbel PA (2008) Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. JACC Cardiovasc Interv 1:111\u2013121","journal-title":"JACC Cardiovasc Interv"},{"key":"2914_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/bmm.10.122","volume":"5","author":"K Schr\u00f6r","year":"2011","unstructured":"Schr\u00f6r K, Huber K, Hohlfeld T (2011) Functional testing methods for the antiplatelet effects of aspirin. Biomark Med 5:31\u201342","journal-title":"Biomark Med"},{"key":"2914_CR3","unstructured":"Highlights of prescribing information, Naprosyn (naproxen) tablets, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/017581s115,018164s065,020067s024lbl.pdf . Accessed 5 Feb 2023"},{"key":"2914_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11239-017-1593-y","volume":"45","author":"PA Gurbel","year":"2018","unstructured":"Gurbel PA, Bliden KP, Zhu J, Troullos E, Centofanti R, Jarvis S, Venkataraman P, Tantry US (2018) Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. J Thromb Thrombolysis 45:18\u201326","journal-title":"J Thromb Thrombolysis"},{"key":"2914_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","volume":"69","author":"IA Reilly","year":"1987","unstructured":"Reilly IA, FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drug. Blood 69:180\u2013186","journal-title":"Blood"},{"key":"2914_CR6","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","volume":"311","author":"AK Pedersen","year":"1984","unstructured":"Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 311:1206\u20131211","journal-title":"N Engl J Med."},{"key":"2914_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11239-020-02334-x","volume":"51","author":"PA Gurbel","year":"2021","unstructured":"Gurbel PA, Bliden KP, Tantry US (2021) Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation. J Thromb Thrombolysis 51:260\u2013264","journal-title":"J Thromb Thrombolysis"},{"key":"2914_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1161\/CIRCULATIONAHA.120.047477","volume":"142","author":"PA Gurbel","year":"2020","unstructured":"Gurbel PA, Bliden KP, Chaudhary R, Tantry US (2020) First in-Human experience with inhaled acetylsalicylic acid for immediate platelet inhibition: Comparison with chewed and swallowed acetylsalicylic acid. Circulation 142:1305\u20131307","journal-title":"Circulation"},{"issue":"79","key":"2914_CR9","first-page":"197","volume":"2022","author":"JS Lawton","year":"2021","unstructured":"Writing Committee Members, Lawton JS, Tamis-Holland JE, Bangalore S et al (2021) ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022(79):197\u2013215","journal-title":"J Am Coll Cardiol"},{"key":"2914_CR10","unstructured":"CFR\u2014Code of Federal Regulations Title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=343.80#:~:text=Vascular%20Indications%20(Ischemic%20Stroke%2C%20TIA,the%20brain%20due%20to%20fibri"},{"key":"2914_CR11","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1161\/CIRCULATIONAHA.106.675587","volume":"115","author":"PA Gurbel","year":"2007","unstructured":"Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US (2007) Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115:3156\u20133164","journal-title":"Circulation"},{"key":"2914_CR12","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","volume":"105","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650\u20131655","journal-title":"Circulation"},{"key":"2914_CR13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","volume":"118","author":"JW Eikelboom","year":"2008","unstructured":"Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators (2008) Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 118:1705\u201312","journal-title":"Circulation."},{"key":"2914_CR14","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1161\/CIRCULATIONAHA.109.900589","volume":"120","author":"AL Frelinger 3rd","year":"2009","unstructured":"Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120:2586\u20132596","journal-title":"Circulation"},{"key":"2914_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD, ADAPT-DES Investigators (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study. Lancet. 382:614\u201323","journal-title":"Lancet."},{"key":"2914_CR16","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1161\/CIRCULATIONAHA.111.085464","volume":"125","author":"JL Reny","year":"2012","unstructured":"Reny JL, Berdagu\u00e9 P, Poncet A, Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group (2012) Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation. 125:3201\u201310","journal-title":"Circulation."},{"key":"2914_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006050","volume":"6","author":"SB Larsen","year":"2017","unstructured":"Larsen SB, Grove EL, Neergaard-Petersen S, W\u00fcrtz M, Hvas AM, Kristensen SD (2017) Reduced antiplatelet effect of aspirin does not predict cardiovascular events in patients with stable coronary artery disease. J Am Heart Assoc 6:e006050","journal-title":"J Am Heart Assoc"},{"key":"2914_CR18","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/eurheartj\/ehm226","volume":"28","author":"M Lordkipanidz\u00e9","year":"2007","unstructured":"Lordkipanidz\u00e9 M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28:1702\u20131708","journal-title":"Eur Heart J"},{"key":"2914_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1586\/14779072.2.4.535","volume":"2","author":"PA Gurbel","year":"2004","unstructured":"Gurbel PA, Bliden KP, Hayes KM, Tantry U (2004) Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2:535\u2013545","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2914_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","volume":"46","author":"US Tantry","year":"2005","unstructured":"Tantry US, Bliden KP, Gurbel PA (2005) Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46:1705\u20131709","journal-title":"J Am Coll Cardiol"},{"key":"2914_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/clinchem\/45.6.882","volume":"45","author":"K Linnet","year":"1999","unstructured":"Linnet K (1999) Necessary sample size for method comparison studies based on regression analysis. Clin Chem 45:882\u2013894","journal-title":"Clin Chem"},{"key":"2914_CR22","first-page":"805","volume":"14","author":"PW L\u00fccker","year":"1992","unstructured":"L\u00fccker PW, Wetzelsberger N, Schettler T, Rogalla K (1992) Pharmacokinetics and relative bioavailability of a new chewable, buffered acetylsalicylic acid tablet formulation in comparison to a conventional plain tablet. Methods Find Exp Clin Pharmacol 14:805\u2013811","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"2914_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5414\/CP204271","volume":"60","author":"D Atar","year":"2022","unstructured":"Atar D, Sarkar S, Kolev E, Mura C, Brosstad F, Theodorsen L, Westen GI, Stribolt-Halvorsen PE (2022) Randomized, open-label, crossover trial comparing the pharmacokinetic profile of a novel oral aspirin solution and a chewed aspirin tablet. Int J Clin Pharmacol Ther 60:430\u2013438","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02914-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02914-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T13:10:48Z","timestamp":1706706648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02914-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["2914"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02914-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"15 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Gurbel has received consulting fees and\/or honoraria from Bayer, Otitopic\/Vectura, Janssen, UpToDate, Cleveland Clinic, Adeno, Wolters Kluwer Pharma, WebMD Medscape, Baron and Budd, North American Thrombosis Forum, Innovative Sciences; institutional research grants from the Haemonetics, Janssen, Bayer, Instrumentation Laboratories, Amgen, Idorsia, Otitopic, Hikari Dx, Novartis, Precision Biologic, Nirmidas Biotech, and R-Pharma International; in addition, Dr. Gurbel has two patents, Detection of restenosis risk in patients issued and Assessment of cardiac health and thrombotic risk in a patient. Dr. Gurbel was an expert witness in a lawsuit associated with Plavix. Other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}